非霍奇金淋巴瘤中双特异性抗体与T细胞导向疗法的现状
The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL.
作者信息
Kordic Austin, Phillips Tycel Jovelle, Weiss Jonathan
机构信息
City of Hope Comprehensive Cancer Center, Department of Hematology and Hematopoietic Cell Transplantation, Division of Lymphoma, Duarte, CA 91010, USA.
Rogel Comprehensive Cancer Center, University of Michigan-Ann Arbor, Ann Arbor, MI 48109, USA.
出版信息
Cancers (Basel). 2025 Mar 31;17(7):1192. doi: 10.3390/cancers17071192.
Relapsed/refractory non-Hodgkin lymphoma (r/r/NHL) is an aggressive disease with overall poor response rates to chemo-immunotherapy and autologous stem-cell transplant, especially in patients with diffuse large B-cell lymphoma. Major improvements in this disease space have come through the incorporation of novel immune therapies, including CD19/CD20 directed CAR-T cells and bispecific antibodies. These exciting new therapies continue to change the landscape of treatment for r/r NHL and have been incorporated in earlier lines of therapy with demonstrated efficacy and patient safety. In this review, the role of these treatments in the management of relapsed/refractory NHL is discussed in detail along with future directions of research.
复发/难治性非霍奇金淋巴瘤（r/r/NHL）是一种侵袭性疾病，对化疗免疫疗法和自体干细胞移植的总体反应率较差，尤其是弥漫性大B细胞淋巴瘤患者。该疾病领域的重大进展来自于新型免疫疗法的纳入，包括靶向CD19/CD20的嵌合抗原受体T细胞（CAR-T细胞）和双特异性抗体。这些令人兴奋的新疗法不断改变着r/r NHL的治疗格局，并已被纳入早期治疗方案，显示出疗效和患者安全性。在本综述中，将详细讨论这些治疗方法在复发/难治性NHL管理中的作用以及未来研究方向。
Zotero 插件